SLC5A2 and heart failure: Based on the most recent guidelines and benefits shown in large major clinical trials, SGLT-2 inhibitors must be considered as essential therapy among heart failure patients, in conjunction with ARNi/ACEi/ARB, MRA, and beta-blockers [4].